share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities

CRISPR Therapeutics | 4：持股变动声明
美股sec公告 ·  03/18 17:46
Moomoo AI 已提取核心信息
On March 15, 2024, Samarth Kulkarni, CEO of CRISPR Therapeutics, completed a stock transaction involving the company's common shares. Kulkarni acquired 20,000 shares through the exercise of derivative securities at a price of $19.12 per share. On the same day, he sold a total of 20,000 shares in two separate open market transactions. The first sale consisted of 10,613 shares at a price of $71.9693 each, while the second involved 9,387 shares sold at $73.0604 per share. Following these transactions, Kulkarni's direct holdings in CRISPR Therapeutics amounted to 208,122 shares. The total market value of the disposed shares was approximately $1,449,628. Additionally, Kulkarni holds an indirect interest in 200,000 shares through The Kulkarni 2023 GRAT, an indirect beneficial ownership structure.
On March 15, 2024, Samarth Kulkarni, CEO of CRISPR Therapeutics, completed a stock transaction involving the company's common shares. Kulkarni acquired 20,000 shares through the exercise of derivative securities at a price of $19.12 per share. On the same day, he sold a total of 20,000 shares in two separate open market transactions. The first sale consisted of 10,613 shares at a price of $71.9693 each, while the second involved 9,387 shares sold at $73.0604 per share. Following these transactions, Kulkarni's direct holdings in CRISPR Therapeutics amounted to 208,122 shares. The total market value of the disposed shares was approximately $1,449,628. Additionally, Kulkarni holds an indirect interest in 200,000 shares through The Kulkarni 2023 GRAT, an indirect beneficial ownership structure.
2024年3月15日，CRISPR Therapeutics首席执行官萨玛斯·库尔卡尼完成了一项涉及公司普通股的股票交易。库尔卡尼通过行使衍生证券以每股19.12美元的价格收购了20,000股股票。同一天，他在两次单独的公开市场交易中共出售了20,000股股票。第一次出售包括10,613股股票，每股价格为71.9693美元，第二次出售涉及以每股73.0604美元的价格出售的9,387股股票。这些交易之后，库尔卡尼在CRISPR Therapeutics的直接持股量为208,122股。已处置股票的总市值约为1,449,628美元。此外，库尔卡尼通过间接实益所有权结构库尔卡尼2023 GRAT间接持有20万股股票的权益。
2024年3月15日，CRISPR Therapeutics首席执行官萨玛斯·库尔卡尼完成了一项涉及公司普通股的股票交易。库尔卡尼通过行使衍生证券以每股19.12美元的价格收购了20,000股股票。同一天，他在两次单独的公开市场交易中共出售了20,000股股票。第一次出售包括10,613股股票，每股价格为71.9693美元，第二次出售涉及以每股73.0604美元的价格出售的9,387股股票。这些交易之后，库尔卡尼在CRISPR Therapeutics的直接持股量为208,122股。已处置股票的总市值约为1,449,628美元。此外，库尔卡尼通过间接实益所有权结构库尔卡尼2023 GRAT间接持有20万股股票的权益。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息